Cortiula F, De Ruysscher D, Steens M, Wijsman R, et al. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations. Eur J Cancer 2023;184:172-178.
PMID: 36931075